Thank you, operator, and a warm welcome to everyone joining us for Bactiguard's second quarter presentation for 2026. I'm joined today by our CFO, Patrick Bach. And I'll take you through the quarter's strategic highlights, and then hand over to Patrick for a closer look at the numbers before we open the line up for your questions. Today's title, "Solid performance driven by revenue growth," captures exactly where we landed this quarter. Strong top-line momentum across the business, confirming that the slower start to the year was simply a matter of timing rather than any change in trend. So let's dive straight into the quarter and start with the numbers. We're pleased to report second quarter net sales growth, excluding currency, of 16%. The main driver was a recovery in BD revenues alongside one of the strongest quarters our Wound Management portfolio has ever recorded. This quarter confirms that the softer start to the year was a matter of timing, not a change in trend, as I said, and our strategy execution is on track. Adjusted EBITDA came in at 5.6 MSEK, up from 4.4 MSEK a year ago, lifted by sales growth and continued cost discipline. It's a good illustration of how top-line growth flows through to earnings in a scalable, license-based business, and it gives us room to keep investing in future growth. Cash flow from operations amounted to 12.4 MSEK, a clear step up from the 1.7 MSEK in the same quarter last year. Strategically, it was an eventful quarter.
Second, we signed a new long-term agreement that deepens our already 35-year partnership with BD. We are seeing growth in the number of patients using Bactiguard-coated implants with Zimmer Biomet, and we had strong momentum in our early partner dialogues. Let me take you through these one at a time. Let's turn to BD. In May, we announced a new long-term agreement with BD, deepening a partnership that goes back to 1990, more than 35 years. Few things illustrate the long-term value that our coating technology creates for partners better than this, or how embedded Bactiguard-coated products become in patient care. Once adopted, what started as a collaboration covering select markets has steadily grown into a true global partnership. Today, it spans the full value chain from technology development to global market execution and is focused on expanding adoption of our infection prevention technology. The restated agreement modernizes the partnership terms and strengthens that foundation further.
It builds on the December 2023 extension under which BD was granted worldwide exclusivity for Bactiguard-coated Foley catheters outside of China. Alongside the commercial terms, a key part of the agreement has been aligning on the regulatory approvals needed to support smooth market transitions, something that's been a shared focus with BD over the past two years, and that has now enabled recent launches in the Nordics, Poland, and parts of the Middle East. We have backed each of these commercialization initiatives with technology training across the regions, and we continue to transition our KOL relationships and former customers to support market access and commercial execution for BD. As I said when we announced the agreement back in May, this is a great example of the power and potential of our license-focused strategy, a partnership that's globally growing and built on shared success. In the quarter, BD revenues came in 50% above the weak second quarter of last year and are also up 8% so far this year, reaching 28.2 MSEK on a reported basis, as in prior quarters. BD revenues are shaped by the timing of concentrate shipments into their supply chain, which can create variation from one quarter to the next. But we continue to see underlying growth both from existing and new markets. Now to Zimmer Biomet, our partnership continues to focus on driving commercial adoption. Bactiguard is leading the work to transition the trauma implants to the MDR regulatory requirements in Europe and supporting the post-market clinical studies. We are very pleased to note that the first of the ongoing multicenter studies is now complete, which is an encouraging step, and the key comparative study is progressing according to plan. We are especially pleased to see growing use of Bactiguard-coated implants in patients. There is still meaningful headroom here, given how small a share of the total trauma market coated implants represent today. Overall, we see the partnership as financially stable, with revenues of 3.8 MSEK in the quarter in line with our expectations, double-digit growth in product sales and clear long-term potential as adoption continues to build.
Let's turn to business development.
We spent a good part of the quarter on new business development, meeting potential future partners at conferences and in direct discussions across the US and Europe. Since launching our five focused therapeutic areas back in March of 2025, we have now completed a full annual calendar of conferences across all of them where we focus on business development activities. The need to find infection prevention solutions is especially recognized in orthopedics, and it is clear that the strongest engagement with Bactiguard is here.
We are also able to capitalize on this category by having rights in various orthopedic segments available for licensing. Since amending our agreement with Zimmer Biomet at the end of 2025, we remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements. We remain focused on advancing these discussions with potential partners while recognizing that in a licensed business, dialogues like these can take time to mature into signed agreements.
Now to Wound Management, which had a standout quarter; the portfolio delivered very strong performance indeed, with 67% revenue growth for the quarter and 25% over the first six months. Our flagship Hydrocyn aqua line led the way, supported by stabilization in sutures, with growth in the portfolio across the Middle East, Europe, and Asia. Tender business in select regions also gave a positive boost in the quarter. Alongside the strong commercial execution, we continue to strengthen the product portfolio, invest in the availability of products in new markets and build out our operational setup in Malaysia. As we've said before, we continue to expect double-digit growth from the combined Wound Management portfolio, fueled by high double-digit growth from Hydrocyn aqua and a stable contribution from sutures. And this quarter confirms that we continue to be on track with that.
Over to Patrick for a closer look at the numbers.